Time filter

Source Type

Unfer V.,Obstetrics and Gynecology Center | Raffone E.,G. Martino Hospital | Rizzo P.,G. Martino Hospital | Buffo S.,Casa di Cura Psichiatrica Colle Cesarano
Gynecological Endocrinology | Year: 2011

Background.Several factors can affect oocyte quality and therefore pregnancy outcome in assisted reproductive technology (ART) cycles. Recently, a number of studies have shown that the presence of several compounds in the follicular fluid positively correlates with oocyte quality and maturation (i.e., myo-inositol and melatonin). Aim.In the present study, we aim to evaluate the pregnancy outcomes after the administration of myo-inositol combined with melatonin in women who failed to conceive in previous in vitro fertilization (IVF) cycles due to poor oocyte quality. Materials and methods.Forty-six women were treated with 4 g/day myo-inositol and 3 mg/day melatonin (inofolic® and inofolic® Plus, Lo.Lipharma, Rome) for 3 months and then underwent a new IVF cycle. Results.After treatment, the number of mature oocytes, the fertilization rate, the number of both, total and top-quality embryos transferred were statistically higher compared to the previous IVF cycle, while there was no difference in the number of retrieved oocyte. After treatment, a total of 13 pregnancies occurred, 9 of them were confirmed echographically; four evolved in spontaneous abortion. Conclusion.The treatment with myo-inositol and melatonin improves ovarian stimulation protocols and pregnancy outcomes in infertile women with poor oocyte quality. © 2011 Informa UK, Ltd.

Condorelli R.A.,University of Catania | Lavignera S.,University of Catania | Di Bari F.,University of Catania | Unfer V.,University of Catania | And 2 more authors.
European Review for Medical and Pharmacological Sciences | Year: 2011

Background and Objectives: Inositol is a component of the vitamin B complex. Myo-inositol (MYO) is the most biologically important form in nature. It is involved in several systemic processes and in mechanisms of signal transduction in the plasma membrane as precursor of second messengers. On the male reproductive function, MYO appears to regulate seminal plasma osmolarity and volume; the expression of proteins essential for embryogenetic development and sperm chemiotaxis; and sperm motility, capacitation, and acrosome reaction. Recently, a seminal antioxidant action has also been suggested. Aim of the Study: To evaluate the effects of MYO on sperm mitochondrial function and apoptosis. Materials and Methods: Spermatozoa isolated from 5 normozoospermic men and from 7 patients with oligo-astheno-teratozoospermia (OAT) were incubated in-vitro with 2 mg/ml of MYO or placebo (control) for 2 hours. After this incubation period, the following sperm parameters were evaluated by flow cytometry: mitochondrial membrane potential (MMP) by JC-1 staining; phosphatidylserine (PS) externalization by annexin V and propidium iodide double staining; and chromatin compactness following propidium iodide staining. Results: MYO did not affect the mitochondrial function of spermatozoa isolated from normozoospermic men, whereas it increased significantly the number of spermatozoa with high MMP and decreased significantly the number of those with low MMP in OAT patients. No effect of MYO was observed on PS externalization and chromatin compactness in both normozoospermic men and OAT patients. Conclusion: The data suggest that MYO is able to ameliorate mitochondrial function in OAT patients. We conclude that this compound may be useful for the treatment of male infertility.

Minozzi M.,University of Rome La Sapienza | Guaraldi C.,Hospital of Valdagno Italy | Unfer V.,Obstetrics and Gynecology Center
Gynecological Endocrinology | Year: 2011

Aim.Compare the effects of a combined contraceptive pill (OCP) in combination with myo-inositol (MI) on endocrine, metabolic, and clinical parameters in patients with polycystic ovary syndrome (PCOS). Methods.One hundred fifty-five patients with PCOS were enrolled in this prospective, open-label clinical study. Patients were assigned to receive oral treatment with OCP alone (estradiol (EE) 30μg/gestodene 75μg) or in combination with myo-inositol 4 g/die, for 12 months. Results.OCP plus MI therapy resulted in a higher reduction of FG score compared with OCP alone therapy. The combined therapy (OCP plus MI) significantly decreased hyperinsulinaemia, by positively affecting the fasting insulin and glucose levels and homeostasis model assessment-insulin resistance parameters, while no significant changes were observed in the OCP group. Androgens serum levels decreased in both groups, but significantly more in the combined therapy group. The lipid profile was improved in the combined therapy group, by reducing low-density lipoprotein cholesterol levels and enhancing high-density lipoprotein cholesterol levels. Conclusions.Our data show that a combination of combined contraceptive pill and MI may be more effective in controlling endocrine, metabolic, and clinical profile in patients with PCOS than OCP alone, and may reduce insulin levels and insulin resistance. Hence, combined treatment may become a more effective long-term therapeutic choice for controlling PCOS symptoms. © 2011 Informa UK, Ltd.

Liu C.,Tsinghua University | Liu C.,Guangxi Medical University | Lin J.,Tsinghua University | Lin J.,Peking University | And 8 more authors.
Scientific Reports | Year: 2015

High-risk human papillomavirus (HPV) type 16, which is responsible for greater than 50% of cervical cancer cases, is the most prevalent and lethal HPV type. However, the molecular mechanisms of cervical carcinogenesis remain elusive, particularly the early steps of HPV infection that may transform normal cervical epithelium into a pre-neoplastic state. Here, we report that a group of microRNAs (microRNAs) were aberrantly decreased in HPV16-positive normal cervical tissues, and these groups of microRNAs are further reduced in cervical carcinoma. Among these miRNAs, miR196a expression is the most reduced in HPV16-infected tissues. Interestingly, miR196a expression is low in HPV16-positive cervical cancer cell lines but high in HPV16-negative cervical cancer cell lines. Furthermore, we found that only HPV16 early gene E5 specifically down-regulated miRNA196a in the cervical cancer cell lines. In addition, HoxB8, a known miR196a target gene, is up-regulated in the HPV16 cervical carcinoma cell line but not in HPV18 cervical cancer cell lines. Various doses of miR196a affected cervical cancer cell proliferation and apoptosis. Altogether, these results suggested that HPV16 E5 specifically down-regulates miR196a upon infection of the human cervix and initiates the transformation of normal cervix cells to cervical carcinoma.

Carlomagno G.,Obstetrics and Gynecology Center | Unfer V.,Obstetrics and Gynecology Center | Buffo S.,Casa di Cura Psichiatrica Colle Cesarano | D'Ambrosio F.,University of Rome Tor Vergata
Human Psychopharmacology | Year: 2011

Objective: Premenstrual dysphoric disorder (PMDD) is a mood disorder disrupting social and/or occupational life of affected women. Premenstrual dysphoric disorder etiology is unknown, although a pivotal role is played by the serotoninergic system. Indeed, one of the most effective treatments is selective serotonin reuptake inhibitors. Several studies have proposed a selective serotonin reuptake inhibitor-like role for myo-inositol, likely due to the fact that myo-inositol is the second messenger of serotonin. In the present study, we aimed to investigate the effect of myo-inositol in the treatment of PMDD. Methods: We used a two-phase clinical trial approach (phase I: placebo washout; phase II: comparisons between treatment and placebo) and treated PMMD patients with two different myo-inositol formulations: powder or soft gel capsules. We decided to test these two formulations because according to the manufacturer, 0.6 of myo-inositol in soft gel capsule has a pharmacokinetic equivalent to 2g of myo-inositol in powder. Results: Our results showed a significant improvement of three different scales: a reduction in the Daily Symptoms Records scale and an improvement of the Hamilton Depression Rating and Clinical Global Impression Severity of Illness scales. Results were similar for both formulations. Conclusions: In the present study, by using a new pharmaceutical formulation, we were able to clearly prove the efficacy of myo-inositol in PMDD. Copyright © 2011 John Wiley & Sons, Ltd.

Discover hidden collaborations